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divided into 4 subgroups (Table). Conclusion: Measuring the combination of TnT and 
BNP after optimized treatment may be valuable for risk assessment of cardiac mortality 
and morbiditv in CHF pts. 
-Risk etr&cation using discharge values of TnT and BNP 
Subgroup I (T-/8-) n=37 II (l-/B+) n=20 Ill (T+/B-) n=9 IV (T+/B+) n=27 
Cardiac death 0 (0%) 0 (0%) 2 (22%) 7 (26%) 
Cardiac event 5 (14%) 6 (30%) 4 (44%) 21 (78%) 
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1015-137 Compensated Cardiac Hypertrophy in Endothelial Nitric 
Oxide Synthase Knockout Mice 
Michael P. Fl&&y, Maria Brown, Hitoshi Takano, lngrid L. Grupp, Jo El Schultz, Sidney 
Murphree, W. Keith Jones, University of Cincinnati, Cincinnati, Ohio, University of 
Louisville, LouisviNe. Kentucky 
Background’. It is well documented that endothelial nitric oxide synthase (eNOS) homozy- 
gous knockout mice (eNOS+) develop sustained arterial hypertension. Because of con- 
troversy over the development of cardiac pathophysiology in these mice, we undertook to 
investigate the cardiac functional and biochemical affects of chronic eNOS ablation. 
Methods: We examined steady state levels of molecular markers of cardiac hypeltrophy 
and heart failure in male eNOS.” and control mice at 18-20, 27-30, 40 and 52 weeks of 
age. Histological examination at 40 weeks of age and cardiac functional analysis using 
the isolated work performing heart preparation were perlormed at 52 weeks of age. 
Results: Hearts from eNOS+ mice exhibited concentric left ventricular hypertrophy, multi- 
focal replacement fibrosis and evidence of myocyie degeneration/death. As mice aged, 
re-induction of atrial natriuretic factor (ANF) and a-skeletal-actin mRNA correlated posi- 
tively with the degree of cardiac hypertrophy. Significant increases in cardiac expression 
of tumor necrosis factor-a (TNF-a) mANA and protein were detected at 27-30 weeks. 
Sarcoplasmic reticulum Ca’+-ATPase (SERCA2a) transcript levels were markedly 
decreased at 27-40 weeks, whereas heads of eNOS”- mice 52 weeks of age demon- 
strated normalized SERCA2a and slightly decreased phospholamban protein levels. 
Although hearts of eNOS’. mice at 52 weeks of age demonstrated no deficit of baseline 
function, there was a blunted response to P-adrenergic stimulation indicative of reduced 
contractile reserve. 
Conclusions: Although eNOS+ mice exhibit myocardial remodeling, including re-induc- 
tion of cardiac fetal genes and dysregulation of TNF-a and SERCA2a, there is no pro- 
gression to failure before 52 weeks of age and in fact these hearts are hypercontractile. 
An increased ratio of SERCA2a protein to phospholamban protein at this timepoint sug- 
gests a mechanism for the long-term physiological compensation that occurs in eNOS”. 
hearts. 
1015-138 New Mutation in Lamin A/C Gene Associated With 
Severe Dilated Cardiomyopathy 
B. Lorenzo Monserrat, Sandra Barral, Rafael Laredo, Beatriz q  ouzas, 
Marisa Crespo. Alfonso Castro-Beiras, Hospital Juan Canalejo, A Corufia, Spain, 
lnstituto de Ciencias de la Salud, A Corufia, Spain. 
Background: Idiopathic Dilated Cardiomyopathy (DCM) is familial in about 30% of the 
cases. Lamin AJC mutations have been identified for causing familial DCM, frecuently 
associated with conduction system disease. We repon here a novel lamin A/C mutation 
with features of severe dilated cardiomyopathy. 
Methods: After informed consent, we studied the lamin A/C gene in 17 patients of 14 dif- 
ferent families with familial DCM. DNA was isolated from frozen blood samples and cod- 
ing regions of lamin A/C were PCR amplified, studied by SSCP and cycle sequenced. 
Results:Three members of one of the families (mother and her two female identical 
twins) developed severe DCM and required cardiac transplantation at 36, 18, and 20 
years old respectively. The father of the index case had died suddenly at 52 years old. At 
diagnosis, the mother was on atrial fibrillation with slow ventricular response. No conduc- 
tion disturbance was present in the twins. 
A new mutation (Arg349Leu) was identified in exon 6 in the three patients. This mutation 
was not present in 22 unaffected relatives and in more than 100 healthy controls. This 
mutation affects a highly conserved region identical in Xenopus laevis. Gallus gallus. 
Rattus norvegicus and humans. 
Conclusions: The Arg349Leu mutation in LMNA A/C gene is associated with a severe 
form of DCM. 
1015-139 Cyclosporine A Treatment Decreases Left Ventricular 
Mass in Mice Expressing a FHC-Linked Troponin T 
(179N) Mutation 
Bioern C. Knollmann, Syevda G. Sirenko, James D. Potter, Kenneth Horton, Neil J. 
Weissman, Georgelow Universify School of Medicine, Washington, Dist. of Columbia, 
Washington Hospital Center, Washington, Dist. of Columbia. 
Cyclosporine A (CyA) prevents cardiac hypertrophy in several animal models, and has 
been proposed as treatment for Familial Hypertrophic Cardiomyopathy (FHC). But with 
the recent report that CyA administration increased cardiac hypertrophy and mortality in 
a mouse model of FHC (aMHC+/403), proposed clinical studies with CyA were aban- 
doned. Because the CyA effect could be specific to this particular mouse model, we 
examined the effect of CyA in a different murine FHC model expressing a troponin T 
(179N) mutation. Methods: Mice expressing human wild-type (Tg-WT), mutant (Tg-l79N) 
Troponin T and non-transgenic littermates (Non-Tg) were treated with CyA (18mqkgl 
day) or vehicle for 4 weeks. LV dimensions, mass and function were measured with 
serial echocardiography in blinded fashion. Results: All mice tolerated CyA treatment. 
LV wall thickness and mass significantly decreased in CyA-treated Tg-l79N mice corn- 
pared to all other groups (table). Systolic function was unchanged. On sacrifice, heart to 
body weight ratio was significantly decreased in CyA-treated compared to vehicle-treated 
Tg-l79N mice, (3.3ztt.lmg/S vs. 3.6M.lmg/g. pc.05). No significant differences in tissue 
histology were found. Blood CyA levels were 453+124 nglml. Conclusion: Unlike in 
mice expressing a a-myosin heavy chain FHC mutation, CyA treatment reduced LV 
mass in mice expressing a FHC-linked Troponin T mutation. Thus, any effect of CyA 
treatment should not be generalized across different FHC-linked mutation or models. 
Effect of CyA treatment on LV-mass (means+ee) 





7 CYA 84t3 72+4” 
7 Vehicle 85t6 116*4 
6 CYA 1 oot3 11255 
6 CvA 67*3 111*6 
1015-140 Effect of Estrogen on Angiotensin Receptors, Matrix 
Metalloproteinases, and Left Ventricular Mass in a 
Transgenic Mouse Model of Human Hypertrophic 
Cardiomyopathy 
Edith Speir, zurxiylc, Kazuyo Takeda, Victor J. Ferrans. Mariappan Muthuchamy, Lameh 
Fananapazir, National Heart, Lung and Blood Institute, Bethesda, Maryland, Texas ABM 
Univarsify, Co//ege Station, Texas. 
Background: Mutahons in a-tropomyosin (Aspl75Asn) can cause familial hypertrophic 
cardiomyopathy (FHCM). Estrogen has been shown to be cardioprotective in several dis- 
eases. This study was designed to determine whether estrogen in physiological doses 
can modify left ventricular (LV) function and hypertrophy by attenuating release of matrix 
metalloproteinases (MMPs) and by regulating angiotensin receptors (AT,) in a transgenic 
mouse model (TGM) expressing Aspl75Asn. 
Methods: TGM and nontransgenic cohorts (NTGM) (20 each) were ovariectomized (0~). 
Slow-release (90 days) estrogen pellets were implanted in 10 mice of each group; the 
other 10 received placebo. Echocardiograms were performed in awake mice at 2 weeks 
after ov (baseline) and after 3 months of daily treadmill exercise. LV mass was assessed 
from M-mode tracings. Mice were then euthanized and some hearts were perfusion-fixed 
and embedded in paraffin, for sectioning; others were processed for frozen sections and 
tissue extracts. lmmunohistochemical staining and immunoblotting were performed. 
Results: Intact TGM and NTGM had LV masses of 77 and 49 mg. and placebo-treated 
and estrogen-treated OY TGM had LV masses of 79 and 60 mg. respectively (p-zO.05, for 
both comparisons). AT-1 receptors, MMP-3 and MMP-13 were increased in untreated ov 
TGM compared to estrogen-treated OY TGM. 
Conclusions: Estrogen replacement significantly reduced LV mass, AT-1 receptors and 
MMP-3 and MMP-13 in a model of FHCM. These findings suggest that estrogen can reg- 
ulate expression of genes involved in matrix metabolism and cardiac fibrosis, which are 
of clinical importance in human patients with FHCM. 
1015-l 59 Determinants of Exercise Capacity in Hypertrophic 
Cardiomyopathy: The Role of Left Ventricular Outflow 
Tract Obstruction 
MunmohanS.Virdee, Yoshihisa Matsumura, Sami Firoozi, Perry M. Elliott, William J. 
McKenna, St George’s Hospital Medical School, London, United Kingdom. 
Background: The influence of left ventricular outflow tract obstruction (LVOTO) on exer- 
cise capacity in patients (pts) with Hypertrophic Cardiomyopathy (HCM) is poorly under- 
stood. 
Methods: 86 pts with HCM (43 +14yrs, 73% symptomatic) underwent upright bicycle 
ergomehy with expiratory gas analysis and echocardiography. Oxygen consumption at 
peak exercise (pkVOP), anaerobic threshold (atV02); 02 pulse at peak exercise (pkO2 
pulse), anaerobic threshold (at02 pulse); and peak workload are expressed as percent- 
age of predicted values. 
Results: 37 pts with resting LVOTO >=30mmHg (58 *2OmmHg, group A), had a lower 
pkVO2 than those without resting LVOTO, 65 219 vs 74 *19%, p=O.O3. In pts without 
resting LVOTO, pkVO2 correlated with peak exercise LVOTO (wO.43, p=O.O03) and 
change in LVOTO during exercise (r=O.44, p=O.O02). Of 49 pts without resting LVOTO. 
16 developed LVOTO >SOmmHg during exercise (group Bi), 33 did not (group Bn). Peak 
exercise LVOTO was lower in group Bi than group A (48 i21 vs 81 r27mmHg. p<O.OOl). 
Table 1. 
There was no difference between the 3 groups for peak heart rate and respiratory quo- 
